TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8859194
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose leucovorin and 5-fluorouracil
Study: 24594851
Drug: Lake Hévíz
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lake Hévíz thermal mineral water therapy (n = 38)
Study: 24594851
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (tap water therapy, n = 39)
Study: 22248752
Drug: Vasoactive drugs
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive drugs (dopamine + norepinephrine)
Study: 22248752
Drug: Vasoactive drugs
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoactive drugs (dopamine + norepinephrine + IABP therapy)
Study: 12038884
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg per day of enteral iron
Study: 12038884
Drug: 12 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg/kg per day of enteral iron
Study: 31551606
Drug: IV1 (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV1 (loading dose 15 mg TXA/kg single intravenous administration)
Study: 31551606
Drug: IV2 (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV2 (loading dose 15 mg TXA/kg + additional dose 15 mg TXA/kg 6 h after the first application)
Study: 31551606
Drug: COMB (IV1
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMB (IV1 + local wash of 2 g of TXA in 50 mL of saline)
Study: 31551606
Drug: TOP (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOP (topical administration of 2 g of TXA in 50 mL of saline)
Study: 28719281
Drug: Handwashing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handwashing with soap and water treatment intervention
Study: 23516412
Drug: Olive leaf
Normalized name: OLIVE LEAF
DrugBank: Olea europaea leaf (DB14745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive leaf extract (OLE) 51.1 mg oleuropein, 9.7 mg hydroxytyrosol per day
Study: 19233390
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor electrical stimulation plus biofeedback (twice a week for 6 weeks, starting 7 days after catheter removal)
Study: 2449013
Drug: Topical clobetasol-17-propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol-17-propionate (CP)
Study: 29924393
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition alone (n = 124 days, 55%)
Study: 29924393
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition in combination with enteral nutrition (n = 96 days, 42%)
Study: 26388465
Drug: Low-concentration protocol
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentration protocol (240 mg I/mL, 80 kVp)
Study: 26388465
Drug: Conventional protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional protocol (350 mg I/mL, 120 kVp)
Study: 12900684
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of pseudoephedrine hydrochloride (D)
Study: 9354192
Drug: mesalazine 500
Normalized name: mesalazine 500 Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalazine 500 mg t.d.s.
Study: 9354192
Drug: oral preparation
Normalized name: Iron bivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral preparation of viable E. coli strain Nissle (Serotype 06: K5: H1)
Study: 24639432
Drug: Lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 20 µg once daily
Study: 18675402
Drug: Enhanced group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced group (weekly moderated online chat sessions)
Study: 12450905
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL CGJ.kg(‐1).d(‐1)
Study: 7193004
Drug: Oral enzyme
Normalized name: alpha-D-galactosidase enzyme Disintegrating Oral Tablet [Beano]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enzyme preparation of trypsin/chymotrypsin (Chymoral 100/F)
Study: 25380743
Drug: Single-port laparoscopic
Normalized name: ADAPTER,ENFIT,20FR,SINGLE PORT,G-TUBE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-port laparoscopic rectal surgery
Study: 25380743
Drug: Conventional laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional laparoscopic rectal surgery
Study: 19714856
Drug: LGG and
Normalized name: Enfamil Nutramigen Toddler with Enflora LGG and Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGG and L. gasseri TMC0356 fermented milk
Study: 17729021
Drug: Duloxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30 or 60 mg daily for the first week, followed by 60, 90, or 120 mg daily for up to 11 weeks)
Study: 14642083
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg bid plus amoxicillin 1000mg bid and levofloxacin 200mg bid
Study: 8545281
Drug: estramustine phosphate
Normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: estramustine phosphate 600 mg/m2‐po daily for up to 2 years
Study: 8545281
Drug: adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjuvant therapy (any)
Study: 1678550
Drug: SKF-94482 400
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF-94482 400 mg at 0830 h
Study: 1678550
Drug: SKF-94482 400
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF-94482 400 mg at 1830 h
Study: 1678550
Drug: SKF-94482 200
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF-94482 200 mg or 300 mg at 0830 and 1830 h
Study: 634895
Drug: Pethidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (50 mg intravenously)
Study: 27710241
Drug: Combination AI/GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination AI/GH
Study: 24423356
Drug: Testosterone and
Normalized name: testosterone and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone and growth hormone (n = 17)
Study: 20047544
Drug: Single-dose azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose azithromycin (30 mg/kg as a single dose)
Study: 20047544
Drug: Amoxycillin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (50 mg/kg/day in two divided doses for a minimum of 7 days)
Study: 12860945
Drug: Lanreotide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide (1 mg three times a day administered subcutaneously)
Study: 12860945
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lanreotide and interferon alfa
Study: 11310381
Drug: Intradermal HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal HBV vaccine (20 mu gms) once a week for 6 weeks
Study: 11310381
Drug: Intradermal HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal HBV vaccine (20 mu gms) twice a week for 6 weeks
Study: 11310381
Drug: Epo and
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epo and twice weekly vaccine (group 2 of phase 2)
Study: 6643397
Drug: Natural history
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural history control (no immediate treatment)
Study: 21949007
Drug: tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: tocilizumab 8 mg/kg every 4 weeks
Study: 16286056
Drug: Rimantadine 100
Normalized name: riMANTAdine 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimantadine 100 mg once daily for 14 days (for influenza A) or placebo (for influenza B)
Study: 10391957
Drug: IgG antibody
Normalized name: CM1 IgG antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibody levels against 38 kDa mycobacterial antigen (measured using ELISA based kits)
Study: 7543113
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg testosterone buciclate (TB) injection
Study: 7543113
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg testosterone buciclate (TB) injection
Study: 7543113
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (600 mg and 1200 mg TB)
Study: 2702967
Drug: Weekly pedometer
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly pedometer distance
Study: 946937
Drug: Low-lactose skim
Normalized name: skim milk
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-lactose skim milk (15 g lactose, 2.5 cups)
Study: 946937
Drug: Low-lactose skim
Normalized name: skim milk
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-lactose skim milk (7.5 g lactose, 2.5 cups)
Study: 946937
Drug: Regular skim
Normalized name: skim milk
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular skim milk (30 g lactose, 2.5 cups)
Study: 946937
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g lactose in water (250 ml)
Study: 946937
Drug: Skim milk
Normalized name: skim milk
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skim milk (500 ml) with 25 g lactose
Study: 946937
Drug: Whole milk
Normalized name: Calcium fortified whole milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole milk (500 ml) with 25 g lactose
Study: 946937
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g lactose in lactose-reduced skim (500 ml)
Study: 946937
Drug: Whole milk
Normalized name: Calcium fortified whole milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole milk (500 ml) with 10 g lactose
Study: 31404466
Drug: 1-week nicotine
Normalized name: nicotine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week nicotine replacement therapy sample (NRTS) including gum/patch and brief advice lasting 10 minutes
Study: 31422079
Drug: Long-term proton
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term proton pump inhibitors (PPIs) therapy (>12 months, n = 85)
Study: 31422079
Drug: No proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: No proton pump inhibitors (non-PPI group, n = 118)
Study: 28358634
Drug: Alfaxalone 3
Normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone 3 mg/kg IV
Study: 28358634
Drug: Alfaxalone 5
Normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone 5 mg/kg IV
Study: 28358634
Drug: Alfaxalone 10
Normalized name: alfaxalone 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone 10 mg/kg IV
Study: 23631544
Drug: Psychoanalytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytic therapy (mean duration: 39 months, mean dose: 234 sessions)
Study: 23631544
Drug: Psychodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic therapy (mean duration: 34 months, mean dose: 88 sessions)
Study: 22987495
Drug: Psychoanalytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytic therapy
Study: 8075874
Drug: maxEPA (eicosapentaenoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: maxEPA (eicosapentaenoic acid 0.178 g g‐1; docosahexaenoic acid 0.116 g g‐1) capsules 10 g per day for 28 days
Study: 2583158
Drug: Caffeinated drink
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated drink at a dose of 5 mg.kg‐1 body mass and at the 3rd and 5th h of marching an additional drink at a dose of 2.5 mg.kg‐1 body mass
Study: 28282221
Drug: Microfracture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microfracture with collagen augmentation (group 2)
Study: 26485914
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (control) with methotrexate (MTX) and prednisone for 6 months
Study: 10381799
Drug: EMD 61753
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 61753 (10 mg p.o.)
Study: 10381799
Drug: EMD 61753
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 61753 (0.1‐3.2 mg i.pl.)
Study: 10381799
Drug: EMD 61753
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 61753 (1.6 mg)
Study: 9007598
Drug: Meropenem monotherapy
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem monotherapy (1 g intravenously every 8 hours)
Study: 9007598
Drug: Cefotaxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (2 g every 8 hours) plus metronidazole (0.5 g intravenously every 8 hours) for 5 to 10 days
Study: 9007598
Drug: Cefotaxime/metronidazole combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime/metronidazole combination
Study: 1645622
Drug: Etoposide 350
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 350 mg/m2
Study: 1645622
Drug: Etoposide 370
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 370 mg/m2
Study: 1645622
Drug: Etoposide (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (dose range 330-370 mg/m2)
Study: 1645622
Drug: Etoposide (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (dose > 300 mg/m2)
Study: 7016157
Drug: Oral misonidazole
Normalized name: metronidazole Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral misonidazole at a dose of 3 g/m2 preceding each of 4 weekly radiation doses
Study: 31547939
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium bicarbonate solution
Study: 31547939
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline solution
Study: 22247354
Drug: Ocrelizumab (OCR)
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab (OCR) 50 mg
Study: 22247354
Drug: Ocrelizumab (OCR)
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab (OCR) 200 mg
Study: 22247354
Drug: Ocrelizumab (OCR)
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab (OCR) 500 mg
Study: 20085455
Drug: FKD peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FKD peptide and p(S/T)F antibody
Study: 16857266
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (COMB)
Study: 16857266
Drug: Medication side-effects
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication side-effects
Study: 8786596
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic at 42 degrees C (amethocaine 1%)
Study: 8786596
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic at 42 degrees C (oxybuprocaine 0.4%)
Study: 8786596
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic at 42 degrees C (lignocaine 4%)
Study: 8786596
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic at room temperature (amethocaine 1%)
Study: 8786596
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic at room temperature (oxybuprocaine 0.4%)
Study: 8786596
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic at room temperature (lignocaine 4%)
Study: 3177196
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Metoprolol + Nifedipine)
Study: 30638411
Drug: Raft-forming chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raft-forming chewable tablets containing Nizatidine
Study: 30638411
Drug: Optimized formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized formulations using sodium alginate, calcium carbonate, and sodium bicarbonate
Study: 26026350
Drug: Dipyrone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone (25 mg/kg)
Study: 26026350
Drug: Meloxicam (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (0.2 mg/kg)
Study: 26026350
Drug: Dipyrone-Meloxicam (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone-Meloxicam (25 mg/kg and 0.2 mg/kg, respectively)
Study: 21236452
Drug: 1 ED(95)
Normalized name: Ed-APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ED(95) of rocuronium (0.3 mg/kg)
Study: 11827684
Drug: Human urotensin
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human urotensin II (hUII) infusion at doses of 100 and 300 pmol min(‐1)
Study: 11827684
Drug: Human urotensin
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human urotensin II (hUII) infusion with nitric oxide clamp
Study: 11827684
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of hUII (3‐300 pmol min(‐1))
Study: 9881390
Drug: Leucocyte-depleting filter
Normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucocyte-depleting filter (group L, n = 20)
Study: 7979954
Drug: PGG-glucan at
Normalized name: B-glucan PGG
DrugBank: Odetiglucan (DB17468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGG-glucan at a dose of 0.1 mg/kg
Study: 7979954
Drug: PGG-glucan at
Normalized name: B-glucan PGG
DrugBank: Odetiglucan (DB17468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGG-glucan at a high dose (1.0 mg/kg or 2.0 mg/kg)
Study: 3377942
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (TTS-fentanyl)
Study: 29630034
Drug: IV DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV DEX 2.0 μg/kg
Study: 14993489
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (10-150 microg) administered once a week or once every 2 weeks
Study: 14993489
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (for subjects with baseline haemoglobin < 11 g/dl)
Study: 11641677
Drug: Vaginally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginally administered misoprostol (25 microg)
Study: 11641677
Drug: Oral plus
Normalized name: Acetaminophen/Dexbrompheniramine Maleate/Pseudoephedrine Hydrochloride 500 MG-3 MG-60 MG Oral Tablet, Extended Release [DRIXORAL PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral plus vaginal misoprostol (25 microg orally, 25 microg vaginally)
Study: 11641677
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (25 microg)
Study: 9695781
Drug: Live tularemia
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live tularemia vaccine (LTV) immunization 15-20 days before surgery
Study: 7723271
Drug: Immunomodulation agents
Normalized name: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulation agents
Study: 30309389
Drug: PQ912 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: PQ912 800 mg bid for 12 weeks
Study: 28809743
Drug: Asunaprevir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asunaprevir (100 mg twice daily) + Daclatasvir (60 mg once daily) for 24 weeks
Study: 23121459
Drug: Thermo-reversible sustained-release
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermo-reversible sustained-release green tea catechin gel
Study: 21515474
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of dexmedetomidine at 0.2 µg·kg(‐1)·h(‐1)
Study: 18435868
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV (types 6/11/16/18) L1 virus‐like‐particle vaccine
Study: 16950199
Drug: Aspirin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (all dosing regimes)
Study: 12969017
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori infection (no treatment prior to end of follow-up)
Study: 8684767
Drug: Microcolposcopy before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcolposcopy before excisional treatment
Study: 1853617
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) treatment (250 mg daily) for 3 months starting from the seventh postoperative day
Study: 1853617
Drug: No ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ASA treatment (control group)
Study: 6603042
Drug: Co-trimoxazole, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole, 2 tabs twice a day for 14 days
Study: 6603042
Drug: Trimethoprim, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim, 250 mg twice a day for 14 days
Study: 17222649
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg zinc